Vitamins
Minerals
Fitness Nutrition
Omega & Fish Oil
Nutritional Drinks
Digestive Care
Diabetic Care
Bone & Joints Care
Respiratory Care
Women Care
Skin Care
Ear Nose Throat
Sexual Wellness
Liver Care
Immunity Boosters
Skin Care
Oral Care
Hair Care
Men Grooming
Baby Food
Baby Hair Care
Baby Skin Care
Baby Bath Care
Diapers
Feminine Hygiene
Women Grooming
Women Nutrition
Blood Glucose
Blood Pressure
Support & Braces
Health Vitals
Test Kits
Nebulizers
Oral Contraceptives
Condoms
Pleasure Enhancers
Protective Gear
Personal & Home
Is a monoclonal antibody that targets rankl (receptor activator of nuclear factor kappa-b ligand).
Treatment of osteoporosis in postmenopausal women at high risk for fracture.
Treatment of osteoporosis in men at high risk for fracture.
Treatment of bone loss associated with androgen deprivation therapy in men with prostate cancer.
Treatment of giant cell tumor of bone (GCTB) in patients who are not candidates for surgery.
Olimab 60mg Inj (Denosumab) binds to RANKL, preventing it from activating its receptor, RANK, on osteoclast precursor cells. This inhibits the formation and function of osteoclasts, the cells responsible for bone resorption. By reducing bone resorption, denosumab increases bone mineral density and reduces the risk of fractures.
Denosumab should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Denosumab is administered as a subcutaneous injection.
The recommended dose for osteoporosis is 60 mg every 6 months.
The recommended dose for GCTB is 120 mg every 4 weeks.
The recommended dose for bone loss associated with androgen deprivation therapy is 120 mg every 4 weeks.
Hypocalcemia (low blood calcium)
Infections
Skin reactions at the injection site
Musculoskeletal pain
Nausea
Constipation
Fatigue
Headache
Dizziness
Atypical femoral fractures (rare but serious)
Alcohol consumption may increase the risk of some side effects, so it's important to discuss your alcohol intake with your doctor.
Denosumab may cause dizziness. Do not drive or operate machinery until you know how this medicine affects you.
Denosumab should not be used during pregnancy. It is unknown if denosumab passes into breast milk. Discuss your pregnancy and breastfeeding plans with your doctor.
Denosumab is not approved for use in children.
Kidney function should be monitored during treatment with denosumab.
Liver function should be monitored during treatment with denosumab.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021588s000lbl.pdf
https://www.medicinenet.com/denosumab/article.htm
https://www.ncbi.nlm.nih.gov/pubmed/20634054
